H&TRC-Health and Technology Research Center, ESTeSL-Lisbon School of Health Technology, Instituto Politécnico de Lisboa, 1990-096 Lisbon, Portugal; iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
H&TRC-Health and Technology Research Center, ESTeSL-Lisbon School of Health Technology, Instituto Politécnico de Lisboa, 1990-096 Lisbon, Portugal.
Biomed Pharmacother. 2021 Jul;139:111558. doi: 10.1016/j.biopha.2021.111558. Epub 2021 Apr 22.
Erythropoietin (EPO) is a hypoxia-induced hormone produced in adult kidneys with erythropoietic and non-erythropoietic effects. In vivo studies represent an important role to comprehend the efficacy and safety in the early phase of repurposing drugs. The aim is to evaluate the potential anti-inflammatory effect of EPO observed in animal models of disease. Following PRISMA statements, electronic database Medline via PubMed platform was used to search articles with the research expression ((erythropoietin [MeSH Terms]) AND (inflammation [MeSH Terms]) AND (disease models, animal [MeSH Terms])). The inclusion criteria were original articles, studies where EPO was administered, studies where inflammation was studied and/or evaluated, non-clinical studies in vivo with rodents, and articles published in English. Thirty-six articles met the criteria for qualitative analysis. Exogenous EPO was used in models of sepsis, traumatic brain injury, and autoimmune neuritis, with an average of 3000 IU/Kg for single and multiple doses, using mice and rats. Biomarkers such as immune-related effectors, cytokines, reactive oxygen species, prostaglandins, and other biomarkers were assessed. EPO has been recognized as a multifunctional cytokine with anti-inflammatory properties, showing its significant effect both in acute and chronic models of inflammation. Further non-clinical studies are suggested for the enlightenment of anti-inflammatory mechanisms of EPO in lower doses, allowing us to understand the translational data for humans.
促红细胞生成素（EPO）是一种缺氧诱导的激素，在成人肾脏中产生，具有促红细胞生成和非促红细胞生成作用。体内研究对于理解药物重新定位早期的疗效和安全性具有重要作用。目的是评估 EPO 在疾病动物模型中观察到的潜在抗炎作用。根据 PRISMA 声明，使用 PubMed 平台上的电子数据库 Medline 搜索具有研究表达的文章（（促红细胞生成素[MeSH 术语]）和（炎症[MeSH 术语]）和（疾病模型，动物[MeSH 术语]））。纳入标准为原始文章、给予 EPO 的研究、研究炎症的研究和/或评估、体内非临床啮齿动物研究以及以英语发表的文章。有 36 篇文章符合定性分析的标准。外源性 EPO 用于败血症、创伤性脑损伤和自身免疫性神经炎模型，单次和多次剂量平均使用 3000IU/Kg，使用小鼠和大鼠。评估了免疫相关效应物、细胞因子、活性氧、前列腺素和其他生物标志物等生物标志物。EPO 已被认为是一种具有抗炎特性的多功能细胞因子，在急性和慢性炎症模型中均显示出显著的效果。建议进行进一步的非临床研究，以阐明 EPO 较低剂量的抗炎机制，从而帮助我们理解针对人类的转化数据。
